Tag:
Inhibitex
Latest Headlines
Latest Headlines
Hep C drug deal frenzy can't be slowed by growing doubts
At the BIO CEO & Investor Conference in New York yesterday, Achillion CEO Michael Kishbauch wrapped up his remarks on the biotech's hepatitis C programs by making it clear that he was angling for
Gilead shares surge as hep C drug scores a cure for big patient population
Gilead Sciences ( $GILD ) received its first bonus from the monster $10.8 billion deal to acquire Pharmasset ( $VRUS ) after CSO Norbert Bischofberger told analysts yesterday evening that PSI-7977
Vertex outlines its survival plan for next-gen hep C combo
At the beginning of 2011, Vertex ( $VRTX ) was basking in the limelight of blockbuster success. Its hepatitis C drug was headed for approval, offering a game-changing approach to the disease, and was
Bristol-Myers reports interferon-free cures in small PhII hep C study
While Bristol-Myers Squibb ( $BMY ) was dealt a setback today on the diabetes front, investigators were reporting progress with a new combination approach to hepatitis C that's raising hopes for an
Bristol CEO touts successful biopharma blitz after big hep C play
Bristol-Myers Squibb ( $BMY ) mounted an enviable makeover from a diversified company to a biopharma force over the past several years, with the famed "String of Pearls" strategy advanced to buy
JPM kicks off with fevered focus on the next big biotech deal
The news of the Bristol-Myers/Inhibitex deal couldn't have been better timed. With the biotech world converging on San Francisco today for the annual JP Morgan confab, there's nothing like a
Bristol bags hot hep C drug developer Inhibitex for $2.5B
Proving once again that hepatitis C is the hottest disease in biotech right now, Bristol-Myers Squibb ( $BMY ) has stepped up to the deal table with a $2.5 billion pact to buy out Inhibitex ( $INHX ), a
Who's next on hep C biotech buyout hit list?
After the big biotech deal comes the big biotech buzz. And one of the big questions on everyone's mind after Gilead Sciences ( $GILD ) announced its $11 billion deal to acquire Pharmasset is, "Who's
New contenders will duke it out with Vertex for the hep C crown
The honeymoon is officially over for Vertex. A mere 6 months after gaining a landmark approval for the hepatitis C drug Incivek and quickly vaulting ahead of Merck's rival drug, grabbing a
Inhibitex skyrockets on promising oral Hep C drug program
The investor frenzy over oral hepatitis C drugs is raging this morning. Inhibitex ( $INHX ), a small Georgia-based developer, has doubled in value today with its top-line data from a mid-stage trial of
